ReviewJournal of hematology & oncology2026
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies.
Review in Journal of hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Claudin18.2 (CLDN18.2) is primarily expressed in gastric epithelial cells, where it plays a crucial role in maintaining the integrity of the gastric mucosal barrier. Its aberrant expression is closely associated with the initiation, progression, and tumor microenvironment (TME) remodeling of gastric cancer(GC). Clinical evidence indicates that CLDN18.2 is highly expressed in a substantial proportion of GC. Notably, its expression appears to be largely independent of established biomarkers such as human epidermal growth factor receptor 2 (HER2) and programmed death-ligand 1 (PD-L1). These features collectively suggest CLDN18.2 as a viable candidate for therapeutic intervention in GC. Increasing evidence suggests that CLDN18.2 positivity is associated with patient prognosis and may indicate a distinctive TME characterized by increased infiltration of CD4⁺ and CD8⁺ T cells, macrophages, and cancer-associated fibroblasts. This review systematically summarizes the biological characteristics of CLDN18.2 and the features of CLDN18.2-positive TME, and provides an overview of emerging therapeutic strategies targeting CLDN18.2. The aim is to elucidate the biological and clinical significance of CLDN18.2 in GC and to provide insights for optimizing future precision therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.